Edition:
United States

Aeterna Zentaris Inc (AEZS.O)

AEZS.O on Consolidated Issue listed on NASDAQ Capital Market

2.18USD
25 Sep 2017
Change (% chg)

$0.05 (+2.35%)
Prev Close
$2.13
Open
$2.12
Day's High
$2.20
Day's Low
$2.11
Volume
119,918
Avg. Vol
2,073,852
52-wk High
$5.59
52-wk Low
$0.78

Latest Key Developments (Source: Significant Developments)

Aeterna Zentaris to pursue FDA registration of Macrilen
Monday, 13 Feb 2017 07:30am EST 

Aeterna Zentaris Inc : Aeterna Zentaris announces plans to pursue FDA registration of Macrilen(tm) . FDA has agreed to consider company's conclusions during a type a meeting . Co concluded that macrilen demonstrated performance supportive of achieving registration with U.S. Food and drug administration . Aeterna Zentaris says co-primary endpoint "negative agreement" with itt, which is considered as more relevant endpoint, was met .Says co-primary endpoint "positive agreement" with itt was not met.  Full Article

Aeterna and Specialised Therapeutics Asia sign exclusive license agreement
Wednesday, 12 Oct 2016 08:00am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Specialised Therapeutics Asia sign exclusive license agreement for the potential marketing of Zoptrex(TM) in Australia and New Zealand . Aeterna Zentaris Inc - company expects to complete phase 3 clinical trial for Zoptrex in 2016 . Aeterna Zentaris Inc - plans to submit a new drug application for Zoptrex(TM) to United States Food And Drug Administration (FDA) in first half of 2017 . Aeterna Zentaris - co to be entitled to receive non-refundable upfront payment in consideration for license to sta of co's IP related to Zoptrex(TM) . Aeterna Zentaris - entitled to non-refundable upfront payment in consideration allso for grant to STA of right to commercialize Zoptrex in territory . Aeterna Zentaris - STA has also agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones . Aeterna zentaris- STA has also agreed to make additional payments to co such as double-digit royalties on future net sales of Zoptrex(TM) in territory . Aeterna Zentaris - STA will be responsible for development, reimbursement, commercialization of product in territory (Australia, New Zealand) .Aeterna Zentaris Inc - supply agreement with STA pursuant to which company will supply zoptrex(TM) to sta for duration of license agreement.  Full Article

Aeterna Zentaris reports Q2 loss per share $0.71
Tuesday, 9 Aug 2016 04:30pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports second quarter 2016 financial and operating results . Q2 loss per share $0.71 .Product development programs on track towards FDA submission in 2017.  Full Article

Aeterna and Rafa Laboratories sign license agreement for Zoptrex in Israel
Monday, 1 Aug 2016 08:30am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Rafa Laboratories sign exclusive license agreement for Zoptrex in Israel . Company expects to complete phase 3 clinical trial in Q3 of 2016 . Company and Rafa have also entered into a supply agreement . Entitled to receive a non-refundable upfront payment in consideration for license to Rafa of intellectual property related to Zoptrex .Company will supply Zoptrex to Rafa for duration of license agreement.  Full Article

Aeterna Zentaris, Orient Europharma sign license agreement for Zoptrex
Friday, 1 Jul 2016 08:30am EDT 

Aeterna Zentaris Inc : Aeterna Zentaris and Orient Europharma Co Ltd sign exclusive license agreement for Zoptrex in Taiwan and Southeast Asia . Co will be entitled to receive non-refundable upfront payment for license to Cyntec of co's intellectual property related to Zoptrex . Company expects to complete Phase 3 clinical trial in Q3 of 2016 for Zoptrex . Cyntec agreed to make additional payments to co upon achieving certain pre-established regulatory and commercial milestones .Company will receive royalties on future net sales of Zoptrex in Taiwan, 9 countries in Southeast Asia.  Full Article

Aeterna Zentaris says IND submission by Sinopharm A-Think
Tuesday, 14 Jun 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris announces IND submission by Sinopharm A-Think .Sinopharm A-Think pharmaceuticals co submitted IND for Zoptrex to Chinese state food and drug administration.  Full Article

Aeterna zentaris to file a NDA for zoptrex in first half of 2017
Monday, 6 Jun 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reconfirms commitment to LHRH-receptor targeting zoptrex during 2016 ASCO annual meeting . Phase III trial for endometrial cancer expected to be completed in Q3 2016 .To file a new drug application for zoptrex in first half of 2017.  Full Article

Aeterna Zentaris reports Q1 loss per share $0.37
Monday, 9 May 2016 05:00pm EDT 

Aeterna Zentaris Inc : Aeterna Zentaris reports first quarter 2016 financial and operating results . Q1 loss per share $0.37 . Aeterna Zentaris Inc says expected average monthly operating burn rate of approximately $2.8 million during remainder of 2016 . Aeterna zentaris inc says Zoptrex(tm) (Zoptarelin Doxorubicin) pivotal phase 3 clinical program on track for completion in Q3 2016 .Says Zoptrex(Tm) Licensee in China and related territories, Sinopharm A-Think pharmaceuticals Co., Ltd., scheduled to file IND in Q2 2016.  Full Article

Aeterna Zentaris Inc announces leadership changes
Thursday, 18 Feb 2016 04:24pm EST 

Aeterna Zentaris Inc:Appoints geneviève lemaire as vice president, Finance and chief accounting officer.Keith Santorelli, the company's former vice president, Finance and chief accounting officer, has left the company.  Full Article

Aeterna Zentaris Announces Closing of US$16.65 Million Public Offering of Common Shares and Warrants
Monday, 14 Dec 2015 12:30pm EST 

Aeterna Zentaris Inc:closing of its previously announced underwritten public offering (of 3.0 million common shares and warrants to acquire 2.1 million common shares with a combined purchase price of US$5.55 for one common share together with a warrant to purchase 0.7 of a common share.generating net proceeds of approximately US$15.0 million.In addition, the Company granted the underwriter a 45-day option to purchase up to an additional 330,000 common shares and/or warrants to purchase up to an additional 231,000 common shares, to cover over-allotments, if any.Prior to closing, the underwriter exercised its over-allotment option with respect to the warrants to acquire an additional 231,000 common shares, resulting in an issuance of warrants to acquire an aggregate of 2,331,000 common shares at closing.Intends to use the net proceeds from the Offering to continue to fund its ongoing drug development activities, for the potential addition of commercialized products to the Company's portfolio, and for general corporate purposes, for working capital and to fund negative cash flow.Maxim Group LLC acted as sole book-running manager, and H.C. Wainwright & Co., LLC acted as financial advisor to the Company in connection with the Offering.  Full Article

BRIEF-Altitude Resources says Kuro Coal to acquire 100 pct interest in Elan coal project

* Altitude resources inc - entered into a share sale deed under which Kuro coal Canada will purchase 100% of Elan coal ltd